Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Mezzanotte

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Seminars in Cell & Developmental Biology|June 12, 2016
Ras signaling through RASSF proteinsHoward Donninger, M Lee Schmidt, Jessica Mezzanotte, et al.
Breast Cancer Research and Treatment|August 14, 2024
Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trialZihan Melink, Maryam B Lustberg, Patrick M Schnell, et al.
Plos One|December 26, 2025
A research protocol using ECG monitoring for detection of palpitations-associated arrhythmias in breast cancer survivorsYing Sheng, Matthew R Fleming, Jessica Mezzanotte-Sharpe, et al.
Biomedicines|November 27, 2025
Exploratory Analysis of the Impact of a Single Dose of Trastuzumab on the Immune Microenvironment in HER2-Positive Early-Stage Breast CancerNikita Bastin, Jessica Mezzanotte-Sharpe, Rebecca Alvarez, et al.
NPJ Breast Cancer|June 21, 2025
A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancerJessica Mezzanotte-Sharpe, Brandie C Taylor, Paula I Gonzalez-Ericsson, et al.
Breast Cancer Research and Treatment|July 4, 2025
Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centersJessica Mezzanotte-Sharpe, Chih-Yuan Hsu, David Choi, et al.
Breast Cancer Research and Treatment|July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Research Square|May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Seminars in Cell & Developmental Biology|June 12, 2016
Ras signaling through RASSF proteinsHoward Donninger, M Lee Schmidt, Jessica Mezzanotte, et al.
Breast Cancer Research and Treatment|August 14, 2024
Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trialZihan Melink, Maryam B Lustberg, Patrick M Schnell, et al.
Plos One|December 26, 2025
A research protocol using ECG monitoring for detection of palpitations-associated arrhythmias in breast cancer survivorsYing Sheng, Matthew R Fleming, Jessica Mezzanotte-Sharpe, et al.
Biomedicines|November 27, 2025
Exploratory Analysis of the Impact of a Single Dose of Trastuzumab on the Immune Microenvironment in HER2-Positive Early-Stage Breast CancerNikita Bastin, Jessica Mezzanotte-Sharpe, Rebecca Alvarez, et al.
NPJ Breast Cancer|June 21, 2025
A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancerJessica Mezzanotte-Sharpe, Brandie C Taylor, Paula I Gonzalez-Ericsson, et al.
Breast Cancer Research and Treatment|July 4, 2025
Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centersJessica Mezzanotte-Sharpe, Chih-Yuan Hsu, David Choi, et al.
Breast Cancer Research and Treatment|July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Research Square|May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Pageof 1